Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II window-of-opportunity study of olaparib in locally advanced triple-negative or germline BRCA-mutated breast cancer
2015-000298-11Phase 2Completed
- Sponsor
- ASST Cremona
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaparib in breast cancer and triple-negative breast cancer (TNBC) (2 arms), sponsored by ASST Cremona. Primary endpoint: Relationship between treatment response and biological markers. Started Dec 2020; status: completed.
02
Drugs
olaparib
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2015-000298-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000298-11.